Adalimumab

A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis. 2015 Jul. doi: 10.1111/1756-185X.12711 Read More

Adalimumab of originator Humira

Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197 Sanjay Bandyopadhyay, Mukesh Mahajan, Tulsi Mehta, Arun K Singh, Aashini Parikh, Ajit K Gupta, Pankaj Kalita, Mihir Patel, Sanjeev Kumar Mendiratta Zydus Research Centre, Biotech Division, Cadila Healthcare Ltd, The Zydus Group, Ahmedabad, Gujarat, India Abstract: ZRC-3197 has been developed indigenously by Cadila Healthcare Ltd as…

Adalimumab

Zydus launches world’s first biosimilar of Adalimumab Access to this therapy will impact 12 million people suffering from auto immune disorders like rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and Ankylosing Spondylitis in India New Delhi, December 9, 2014 After more than a decade long wait, the revolutionary therapy that provided a new lease of…

Adalimumab

Access to this therapy will impact 12 million people suffering from auto immune disorders like rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and Ankylosing Spondylitis in India Zydus Cadila announced the launch of its biosimilar Adalimumab, following an approval from the Drug Controller General (India). According to a press release, the biosimilar was developed by…

Adalimumab

Zydus Cadila launched the biosimilar version of Adalimumab, which is the world’s first biosimilar made end-to-end in India. Sharvil Patel, Deputy MD, Cadila Healthcare says the important this is to look at access or affordability.

Adalimumab

NEW DELHI: Drug firm Zydus Cadila today launched biosimilar of Adalimumab, used for treatment of autoimmune disorders, at a price much lower than the innovator drug in India. Developed by Zydus Research Centre, the biosimilar has been approved by the Drug Controller General of India and will be marketed under the brand name ‘Exemptia’ at…

Adalimumab

New Delhi, Dec 9: Zydus Cadila has launched a biosimilar of Adalimumab, which is used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and Ankylosing Spondylitis. Though the innovator drug is currently still under patent in the US, it is not sold in India. The US patent is expected to expire in…

Adalimumab - Exemptia

(Reuters) – Drugmaker Cadila Healthcare Ltd said on Tuesday it launched in India the first biosimilar version of the anti-inflammatory medicine adalimumab, the world’s top-selling drug, at a fifth of its U.S. price. The drug’s branded version is sold under the name Humira by U.S. firm AbbVie Inc, and costs $1,000 for a vial in…

Adalimumab

Access to this therapy will impact 12 million people suffering from auto immune disorders like rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and Ankylosin Spondylitis in India After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune…

© 2017 Cadila Healthcare Ltd. All Rights Reserved. | CompuBrain